MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups | npj Breast Cancer
Verzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study | Eli Lilly and Company
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer
Progression-free survival. a Investigator-assessed and b Independent... | Download Scientific Diagram
K-M curve and parametric survival distributions for OS. OS, overall... | Download Scientific Diagram
PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar
MONARCH 2: Abemaciclib plus fulvestrant improves overall survival | MDedge Hematology and Oncology
Dana-Farber News on Twitter: "#BreastCancer results of monarcHER found abemaciclib + trastuzumab +/- fulvestrant was associated w/numerically improved overall survival when compared to chemo + trastuzumab among pts w/HR+, HER2+ advanced breast
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. | Semantic Scholar
Update Shows Long-Term Survival Benefit with Abemaciclib Plus
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer | Future Oncology
JCM | Free Full-Text | Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study - Annals of Oncology
PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar
FDA Provides Insight Into Abemaciclib Approval for High-Risk Early Breast Cancer
Abemaciclib regimen shows further signs of benefit in advanced breast cancer subgroup
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer | SpringerLink
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text
Combination of abemaciclib and adjuvant hormone therapy increases invasive disease-free survival in high-risk early breast cancer RH + HER2- Onco Americas
Abemaciclib plus aromatase inhibitor in advanced breast cancer